Blood cancer Archives

Produced by Inpart

19 May 2025

Oncology R&D trends and breakthrough innovations

Explore the latest in oncology R&D with Inpart’s new trends report, featuring emerging technologies, breakthrough innovations, and expert insights shaping the future of cancer research.

May 19, 2025

Produced by Inpart

Podcast 1 Sep 2023

Beyond Biotech podcast 61 – Blood Cancer Awareness Month

On this week’s podcast, to recognize Blood Cancer Awareness Month, we have a conversation with Affimed’s CMO, Andreas Harstrick, to talk about blood cancers, and what Affimed is doing to tackle blood cancers. One of the main challenges in treating blood cancers is the limited options for therapeutic intervention. Treatment relies primarily on chemotherapy, which […]

September 1, 2023

In Depth 26 Jul 2023

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine

The first-ever antibody-drug conjugate (ADC) to be approved, gemtuzumab ozogamicin, raised hope for a new class of drugs to treat cancer. But the drug was then withdrawn following a black box warning after patients experienced adverse side effects, and there had been fatalities. But this didn’t discourage biopharmas looking to create safer alternatives from expediting […]

July 26, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 9 Jun 2023

Chronic myeloid leukemia: Novartis survey signals need for better patient-physician communication

Only 19% to 26% of patients with chronic myeloid leukemia (CML) discuss treatment decisions with their physician, a survey by Swiss-based pharmaceutical Novartis has revealed. The Survey of Unmet Needs in CML (CML SUN), which investigated how patients and physicians felt about current treatment options, joint decision-making, and treatment satisfaction, also found that 39% to […]

June 9, 2023 - 4 minutesmins - By Roohi Mariam Peter

News and Trends 10 May 2023

Scientists create first CRISPR-based drug candidate targeting the microbiome

A new CRISPR-based drug candidate targeting E. coli in the gut microbiome is in phase 1 clinical trials. According to a new paper published in Nature Biotechnology, it may improve the well-being of blood cancer patients and reduce their mortality rate from E. coli infections. Many people have experienced infections from E. coli, which are […]

May 10, 2023 - 6 minutesmins - By Jim Cornall

News and Trends 23 Feb 2023

New promising targeted drug for a rare leukemia

Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone. Venetoclax is a new targeted therapy option for the treatment of acute myeloid leukemia (AML). It was recently granted marketing authorization in Finland. Venetoclax works by sensitizing cancer cells to programmed cell […]

February 23, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 31 Jan 2023

Singapore researchers use old drug as new acute leukemia treatment

A team of researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore, has revisited an existing drug to combat a type of blood cancer called T-cell acute lymphoblastic leukemia, or T-ALL. The research was led by Takaomi Sanda and Lim Fang Qi. The drug, PIK-75, was initially discovered […]

January 31, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 24 Jan 2023

First leukemia patient dosed with SMART101

Smart Immune has announced that the first adult leukemia patient has been dosed with SMART101, a T-cell progenitor cell injection derived from donor stem cells using ProTcell at Memorial SloanKettering Cancer Center (MSK). The phaseI/II trial is a multicenter, open-label, first-in-human study expected to enroll up to 36 adult and pediatric patients with hematological malignancies, […]

January 24, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 22 Dec 2022

First CAR-T technology trial for patients with T-cell leukemia subtype authorized

The Spanish Agency of Medicines and Medical Products (AEMPS) has approved the CARxALL clinical trial led by the company OneChain Immunotherapeutics (OCI). It will be the world’s first trial with CAR-T technology for patients with a subtype of T-cell leukemia. The CARxALL trial will evaluate, for the first time, the CAR-T CD1a (OC-1) therapy. This […]

December 22, 2022 - 4 minutesmins - By Jim Cornall

In Depth 20 Dec 2022

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Patient-derived CAR-T immunotherapies have dominated the cancer immunotherapy space over the last decade. The EU approval of Atara Biotherapeutics’ Ebvallo marks the first immunotherapy based on T cells sourced from healthy donors. Since the approvals of Kymriah and Yescarta in 2017, CAR-T immunotherapies have changed the way we treat rare forms of blood cancer. In […]

December 20, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 3 Oct 2022

Estrella and TradeUP merge to become publicly traded company

Estrella Biopharma, Inc. and TradeUP Acquisition Corp. have entered into a definitive business combination agreement that will result in Estrella becoming a publicly listed company. Upon closing of the transaction, TradeUP will be renamed Estrella Immunopharma, Inc. Estrella Biopharma is a preclinical-stage biopharmaceutical company developing CD19-targeted ARTEMIS T-cell therapies under certain license agreements with the […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 28 Sep 2022

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies

Scribe Therapeutics has entered into an agreement with Sanofi which will allow Sanofi use of its CRISPR genome editing technologies. Scribe Therapeutics’ custom genome editing and delivery tools called CasX-Editors (XE) based on foundations such as the CasX enzyme will enable genetic modification of natural killer (NK) cell therapies for cancer and will support Sanofi’s […]

September 28, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Blood cancer

Oncology R&D trends and breakthrough innovations

Beyond Biotech podcast 61 – Blood Cancer Awareness Month

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine

Chronic myeloid leukemia: Novartis survey signals need for better patient-physician communication

Scientists create first CRISPR-based drug candidate targeting the microbiome

New promising targeted drug for a rare leukemia

Singapore researchers use old drug as new acute leukemia treatment

First leukemia patient dosed with SMART101

First CAR-T technology trial for patients with T-cell leukemia subtype authorized

Ebvallo approval ushers in off-the-shelf T-cell immunotherapies

Estrella and TradeUP merge to become publicly traded company

Scribe Therapeutics enters into agreement with Sanofi for use of its CRISPR technologies

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!